Skip to main content

#Coronavirus Disease Research #References (by AMEDEO, April 12 '25)

Image
By G.M.

 


    Br J Anaesth

  1. GILLIS C, Hasil L, Keane C, Brassard D, et al
    A multimodal prehabilitation class for Enhanced Recovery After Surgery: a pragmatic randomised type 1 hybrid effectiveness-implementation trial.
    Br J Anaesth. 2025 Apr 7:S0007-0912(25)00153-9. doi: 10.1016/j.bja.2025.
    PubMed         Abstract available


    Clin Infect Dis

  2. IOANNOU GN, Berry K, Rajeevan N, Li Y, et al
    Target Trial Emulation of Severe Acute Respiratory Syndrome Coronavirus 2 Infection Versus No Infection and Risk of Post-Coronavirus Disease 2019 Conditions in the Omicron Variant Versus Prior Eras.
    Clin Infect Dis. 2025 Apr 10:ciaf087. doi: 10.1093.
    PubMed         Abstract available


    Int J Infect Dis

  3. JOLLIVET O, Urchueguia-Fornes A, Chung-Delgado K, Johannesen CK, et al
    Respiratory Syncytial Virus hospitalisation burden in children below 18 years in six European countries (2016-2023) pre- and post-COVID-19 pandemic.
    Int J Infect Dis. 2025 Apr 7:107903. doi: 10.1016/j.ijid.2025.107903.
    PubMed         Abstract available


    J Med Virol

  4. LIU J, Guo L, Zhong J, Wu Y, et al
    Proteomic Analysis of 442 Clinical Plasma Samples From Individuals With Symptom Records Revealed Subtypes of Convalescent Patients Who Had COVID-19.
    J Med Virol. 2025;97:e70203.
    PubMed         Abstract available

  5. ZHANG Y, Pu D, Liu Q, Li B, et al
    Epidemic Outbreak of Respiratory Syncytial Virus Infection After the end of the Zero-COVID-19 Policy in China: Molecular Characterization and Disease Severity Associated With a Novel RSV-B Clade.
    J Med Virol. 2025;97:e70343.
    PubMed         Abstract available

  6. GUSTANI-BUSS E, Buss CE, Biagi CAO, Oliveira IM, et al
    Unveiling the Dynamics of SARS-CoV-2 Gamma and Delta Waves in Parana, Brazil - Delta Displacing a Persistent Gamma Through Alternative Routes of Dispersal.
    J Med Virol. 2025;97:e70318.
    PubMed         Abstract available

  7. SUN P, Liu Q, Yuan S, Wang XT, et al
    SARS-CoV-2 Membrane Protein Induces MARCHF1/GPX4-Mediated Ferroptosis by Promoting Lipid Accumulation.
    J Med Virol. 2025;97:e70328.
    PubMed         Abstract available


    J Travel Med

  8. PATEL P, Freedman DO
    Considerations for prevention and standby emergency treatment for travellers at high- risk of COVID-19 hospitalization.
    J Travel Med. 2025 Apr 4:taaf029. doi: 10.1093.
    PubMed        


    J Virol

  9. ZHOU B, Gui Q, Liu C, Guo H, et al
    Structure and function of an unusual R452-dependent monoclonal antibody against SARS-CoV-2.
    J Virol. 2025 Apr 8:e0184424. doi: 10.1128/jvi.01844.
    PubMed         Abstract available


    Lancet

  10. SUN L, Selbie D, Khan AS, Karim SSA, et al
    Mobilising national and regional assets and non-state actors for pandemic preparedness.
    Lancet. 2025 Apr 3:S0140-6736(25)00630-0. doi: 10.1016/S0140-6736(25)00630.
    PubMed        

  11. YUNAS I, Islam MA, Sindhu KN, Devall AJ, et al
    Causes of and risk factors for postpartum haemorrhage: a systematic review and meta-analysis.
    Lancet. 2025 Apr 3:S0140-6736(25)00448-9. doi: 10.1016/S0140-6736(25)00448.
    PubMed         Abstract available


    Lancet Infect Dis

  12. CHODICK G
    Long-term infectious sequelae after SARS-CoV-2 infection should be considered in mild cases too.
    Lancet Infect Dis. 2025 Apr 1:S1473-3099(25)00074.
    PubMed        

  13. BEJON P, Agweyu A, Ochola-Oyier LI, Hamaluba M, et al
    Rethinking the evidence on COVID-19 in Africa.
    Lancet Infect Dis. 2025 Apr 4:S1473-3099(25)00071.
    PubMed         Abstract available

  14. SAWANO M, Bhattacharjee B, Caraballo C, Khera R, et al
    Nirmatrelvir-ritonavir versus placebo-ritonavir in individuals with long COVID in the USA (PAX LC): a double-blind, randomised, placebo-controlled, phase 2, decentralised trial.
    Lancet Infect Dis. 2025 Apr 3:S1473-3099(25)00073.
    PubMed         Abstract available

  15. CAI M, Xu E, Xie Y, Al-Aly Z, et al
    Rates of infection with other pathogens after a positive COVID-19 test versus a negative test in US veterans (November, 2021, to December, 2023): a retrospective cohort study.
    Lancet Infect Dis. 2025 Apr 1:S1473-3099(24)00831.
    PubMed         Abstract available


    Life Sci

  16. AZEEM M, Cancemi P, Mukhtar F, Marino S, et al
    Efficacy and limitations of SARS-CoV-2 vaccines - A systematic review.
    Life Sci. 2025;371:123610.
    PubMed         Abstract available


    Nature

  17. THOMPSON B
    From Hippocrates to COVID-19: the scientific fight to prove diseases can be airborne.
    Nature. 2025 Apr 7. doi: 10.1038/d41586-025-00960.
    PubMed        

  18. LEDFORD H, Kozlov M
    Long COVID activists fought Trump team's research cuts and won - for now.
    Nature. 2025 Apr 7. doi: 10.1038/d41586-025-00995.
    PubMed        


    Science

  19. KAISER J
    Health agencies reeling as leaders, staff slashed.
    Science. 2025;388:134-135.
    PubMed         Abstract available

  20. JOOSTE I
    No one can replace the U.S. as it retreats from global health.
    Science. 2025;388:138-139.
    PubMed         Abstract available
Labels:

Comments

Post a Comment

Popular posts from this blog

#Neuroinvasive #Oropouche virus in a patient with #HIV from extra-Amazonian #Brazil

By G.M.
{Excerpt} A novel reassortant Oropouche virus (OROV) lineage (with medium [M], large [L], and small [S] RNA segments : M1L2S2) has driven Brazil's largest and most geographically widespread OROV epidemic , expanding beyond the endemic Amazon basin to establish local transmission across multiple Brazilian states and other previously unaffected Latin American countries . The rapid spread of this lineage underscores its evolutionary potential and reinforces its significance as a public health threat .1 Similar to chikungunya and Zika viruses, expanding arboviruses can exhibit unexpected clinical and epidemiological shifts , including vertical transmissions , neuroinvasive effects, and potentially fatal outcomes.2–4 Although OROV typically causes self-limited febrile illness, accumulating clinical and experimental evidence suggests neurotropic potential .5 This Correspondence describes the first confirmed case of neuroinvasive OROV infection caused by the emergent M1L2S2 lineage in ext...
Post a Comment
Read more »

No evidence of immune #exhaustion after repeated #SARS-CoV-2 #vaccination in vulnerable and healthy populations

By G.M.
Abstract Frequent SARS-CoV-2 vaccination in vulnerable populations has raised concerns that this may contribute to T cell exhaustion , which could negatively affect the quality of immune protection. Herein, we examined the impact of repeated SARS-CoV-2 vaccination on T cell phenotypic and functional exhaustion in frail older adults in long-term care (n = 23), individuals on immunosuppressive drugs (n = 10), and healthy adults (n = 43), in Canada . Spike-specific CD4+ and CD8+ T cell levels did not decline in any cohort following repeated SARS-CoV-2 vaccination, nor did the expression of exhaustion markers on spike-specific or total T cells increase. T cell production of multiple cytokines (i.e. polyfunctionality) in response to the spike protein of SARS-CoV-2 did not decline in any cohort following repeated vaccination. None of the cohorts displayed elevated levels of terminally differentiated T cells following multiple SARS-CoV-2 vaccinations. Thus, repeated SARS-CoV-2 vaccination was...
Post a Comment
Read more »

Chimeric #hemagglutinin and #M2 #mRNA #vaccine for broad #influenza subtype protection

By G.M.
Abstract Since multiple and unpredicted influenza viruses cause seasonal epidemics and even high-risk pandemics , developing a universal influenza vaccine is essential to provide broad protection against various influenza subtypes. Combined with the mRNA lipid nanoparticle-encapsulated (mRNA-LNP) vaccine platform and chimeric immunogen strategy , we developed a novel cocktail mRNA vaccine encoding chimeric HAs (cH5/1-BV, cH7/3) and intact M2 (termed Fluaxe), which confers broad protection against major circulating IAVs and IBVs , as well as highly pathogenic avian influenza . Two-dose intramuscular immunization of Fluaxe in mice elicited cross-reactive neutralizing antibodies , T cell responses, and long-lived immunity, resulting in robust protection against multiple lethal influenza virus infections and severe acute lung injuries . In particular, intramuscular administration stimulated systemic immunity together with a prominent lung tropism of memory cells . Moreover, Fluaxe immuniza...
Post a Comment
Read more »